Compare Liberty Energy Inc. Class A common stock (LBRT) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Liberty Energy (LBRT) trades at $19.11, up 0.68% today, with a bearish technical signal but strong analyst support. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue reached $4.01B in 2025, though net margins are thin at 2.92%. Valuation metrics like P/E of 25.82 and P/S of 0.75 suggest mixed attractiveness relative to profitability.

Outlook is cautiously optimistic given earnings momentum and a $28.38 consensus price target, but risks include margin pressure from rising costs and execution challenges in expanding into data center power. The stock's proximity to its 52-week low of $19.00 highlights downside vulnerability if Q3 results disappoint.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.